Tag Archives: Clinical Trials

Watch out for these red flags in COVID-19 vaccine trials

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

syringes

Photo: Jernej Furman via Flickr

In a previous blog post, I discussed what reporters look for when they dig into the data from the various COVID-19 vaccine clinical trials. That post covered the do’s, but it didn’t cover the red flags that reporters should watch for as well.

Vinay Prasad, M.D., a hematologist-oncologist and associate professor of medicine at the University of California, San Francisco, followed up his Twitter thread on what to look for with a list of common problems in vaccine clinical trials that journalists also should monitor: Continue reading

New blood test shows promise in predicting Alzheimer’s disease

About Liz Seegert

Liz Seegert (@lseegert), is AHCJ’s topic editor on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News, the Connecticut Health I-Team and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.

Photo: Thirteen Of Clubs via Flickr

You may have read reports about a new blood test to detect early brain changes that can flag common markers of Alzheimer’s disease. It’s moved one step closer to clinical use and could be a game-changer, according to researchers.

Up to two decades before people develop the characteristic memory loss and confusion of Alzheimer’s disease, damaging clumps of protein start to build up in their brains. Continue reading

Reporter takes deep dive into alternative Alzheimer’s therapy

About Liz Seegert

Liz Seegert (@lseegert), is AHCJ’s topic editor on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News, the Connecticut Health I-Team and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.

Photo: Joy Weinberg via Flickr

There’s no doubt that a diagnosis of Alzheimer’s disease is devastating for both the person who receives it and for their family.

Although it’s the sixth leading cause of death in the U.S., affecting nearly 6 million people, finding a cure or even a long-term treatment has proven elusive. Most drugs never make it out of Phase I or II trials. Continue reading

Don’t neglect the human stories — and human pain — behind clinical trials

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

Most often, reporting on medical studies means recounting numbers, demographic details, findings and statistical probability values that are so abstract that it’s easy to forget they all refer to actual people enrolled in the study. With epidemiological studies, the researchers themselves often never meet the people they report on, especially if it’s a retrospective study that primarily relies on electronic medical records.

But clinical trials are a different story. Continue reading

Increased optimism about new Alzheimer’s drugs, tests

About Liz Seegert

Liz Seegert (@lseegert), is AHCJ’s topic editor on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News, the Connecticut Health I-Team and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.

Photo: AJ Cann via Flickr

You may have recently heard about the multimillion-dollar donation that Bill Gates and Leonard Lauder made to support research into biomarkers for early detection of Alzheimer’s disease and related dementias.

The Diagnostics Accelerator initiative is part of the Alzheimer’s Drug Discovery Foundation’s (ADDF) effort to speed diagnosis and develop drugs that can prevent, treat, and cure the disease. Lauder was an ADDF co-founder. Continue reading

NIH to require more transparency for clinical trials

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

Photo: Iwan Gabovitch via Flickr

The ongoing push for open science and greater transparency in medical research just notched another win following new rules from the National Institutes of Health regarding federally funded research involving humans. As the Wall Street Journal recently reported, the NIH is broadening the definition of clinical trials for what must be registered and reported at ClinicalTrials.gov.

“Researchers must now report their findings on the site within a year of study completion or risk losing future funding,” wrote reporters Daniela Hernandez and Amy Dockser Marcus. Continue reading